Occident Group

Founded in 2012, Occident Group is an owner-managed venture capital investor based in Munich and Zug. It focuses on investing in deep tech start-ups, particularly those originating from scientific research, with a emphasis on life sciences and industrial tech sectors. The company supports these start-ups from the seed stage onwards, providing long-term financial backing and extensive experience to enable their success.

Cédric Barra

Senior Investment Manager, Life Sciences

Mirco Müller

Junior Investment Manager (Life Sciences)

Michael Pauer

Chief Investment Officer

Simon von Spannenberg

Investment Manager, Industrial Tech

Past deals in Zurich

Hemotune

Series B in 2024
Hemotune AG is a medical device company based in Zürich, Switzerland, founded in 2016. The company specializes in developing a therapeutic blood purification platform that utilizes magnetic blood purification technology to address infections and other health ailments. Hemotune's innovative approach involves the use of magnetic beads, which facilitate the selective and efficient removal of large biomolecules from the bloodstream. This technology focuses on the immunological aspects of conditions like sepsis, allowing for targeted treatment that addresses multiple disease pathways. By enhancing the purification of blood in acute care settings, Hemotune aims to improve patient outcomes for those suffering from blood-related diseases.

Invasight

Seed Round in 2022
Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.

Hemotune

Series B in 2022
Hemotune AG is a medical device company based in Zürich, Switzerland, founded in 2016. The company specializes in developing a therapeutic blood purification platform that utilizes magnetic blood purification technology to address infections and other health ailments. Hemotune's innovative approach involves the use of magnetic beads, which facilitate the selective and efficient removal of large biomolecules from the bloodstream. This technology focuses on the immunological aspects of conditions like sepsis, allowing for targeted treatment that addresses multiple disease pathways. By enhancing the purification of blood in acute care settings, Hemotune aims to improve patient outcomes for those suffering from blood-related diseases.

Hemotune

Series A in 2020
Hemotune AG is a medical device company based in Zürich, Switzerland, founded in 2016. The company specializes in developing a therapeutic blood purification platform that utilizes magnetic blood purification technology to address infections and other health ailments. Hemotune's innovative approach involves the use of magnetic beads, which facilitate the selective and efficient removal of large biomolecules from the bloodstream. This technology focuses on the immunological aspects of conditions like sepsis, allowing for targeted treatment that addresses multiple disease pathways. By enhancing the purification of blood in acute care settings, Hemotune aims to improve patient outcomes for those suffering from blood-related diseases.

Numbrs

Venture Round in 2018
Numbrs, headquartered in Zurich, Switzerland, is a customer-focused financial services company. It offers a mobile banking platform that allows users to manage their existing bank accounts and personal finances, and purchase financial products from various providers at competitive prices. Numbrs, with over 100 employees, does not operate as a bank itself.

Versantis

Series A in 2017
Versantis AG is a Swiss pharmaceutical company focused on developing innovative medicines and diagnostics for liver diseases. Founded in 2015 and based in Zurich, Versantis aims to address significant unmet medical needs for patients globally. Its lead candidate, VS-01, is currently in preclinical development and has the potential to be the first treatment for acute liver disease while simultaneously supporting multiple failing organs. VS-01 has received Orphan Drug Designation for its application in acute liver failure. The company also has additional treatments in its pipeline, including VS-02 and VS-03, which target chronic liver diseases and drug intoxications, respectively. These developments represent substantial market opportunities and underscore Versantis' commitment to improving patient outcomes for millions affected by liver conditions and related disorders.

Numbrs

Venture Round in 2017
Numbrs, headquartered in Zurich, Switzerland, is a customer-focused financial services company. It offers a mobile banking platform that allows users to manage their existing bank accounts and personal finances, and purchase financial products from various providers at competitive prices. Numbrs, with over 100 employees, does not operate as a bank itself.

iMusician

Venture Round in 2015
iMusician Digital AG is a Swiss-based online platform founded in 2007, dedicated to empowering musicians in managing, selling, and monetizing their music. Located in Zurich, the company offers a comprehensive suite of tools that enables artists to distribute their music across major streaming services and sales platforms. iMusician focuses on simplifying the process for musicians by providing real-time sales tracking and copyright management, allowing them to concentrate on their creative work. With a small, passionate international team, iMusician Digital strives to support artists in navigating the complexities of the music industry and maximizing their revenue potential.

iMusician

Series A in 2014
iMusician Digital AG is a Swiss-based online platform founded in 2007, dedicated to empowering musicians in managing, selling, and monetizing their music. Located in Zurich, the company offers a comprehensive suite of tools that enables artists to distribute their music across major streaming services and sales platforms. iMusician focuses on simplifying the process for musicians by providing real-time sales tracking and copyright management, allowing them to concentrate on their creative work. With a small, passionate international team, iMusician Digital strives to support artists in navigating the complexities of the music industry and maximizing their revenue potential.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.